Luis Robles-Diaz
Overview
Explore the profile of Luis Robles-Diaz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
369
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Weir A, Kang E, Meagher N, Nelson G, Ghatage P, Lee C, et al.
Br J Cancer
. 2022 Nov;
128(1):137-147.
PMID: 36323878
Background: Recently, we showed a >60% difference in 5-year survival for patients with tubo-ovarian high-grade serous carcinoma (HGSC) when stratified by a 101-gene mRNA expression prognostic signature. Given the varied...
2.
Riesco-Martinez M, Fernandez-Martos C, Gravalos-Castro C, Espinosa-Olarte P, La Salvia A, Robles-Diaz L, et al.
Cancers (Basel)
. 2020 Dec;
12(12).
PMID: 33291454
Multimodality treatment is a standard of care for LARC, but the optimal sequencing of the treatment modalities remains unclear. Several randomized clinical trials (RCTs) compared total neoadjuvant treatment (TNT) vs....
3.
Cordero-Barreal A, Caleiras E, Lopez de Maturana E, Monteagudo M, Martinez-Montes A, Leton R, et al.
J Clin Endocrinol Metab
. 2020 Aug;
105(11).
PMID: 32791518
Context: The identification of markers able to determine medullary thyroid cancer (MTC) patients at high-risk of disease progression is critical to improve their clinical management and outcome. Previous studies have...
4.
Martins F, Couturier D, Paterson A, Karnezis A, Chow C, Nazeran T, et al.
Br J Cancer
. 2020 Jun;
123(5):793-802.
PMID: 32555365
Background: PTEN loss is a putative driver in histotypes of ovarian cancer (high-grade serous (HGSOC), endometrioid (ENOC), clear cell (CCOC), mucinous (MOC), low-grade serous (LGSOC)). We aimed to characterise PTEN...
5.
Goode E, Block M, Kalli K, Vierkant R, Chen W, Fogarty Z, et al.
JAMA Oncol
. 2017 Oct;
3(12):e173290.
PMID: 29049607
Importance: Cytotoxic CD8+ tumor-infiltrating lymphocytes (TILs) participate in immune control of epithelial ovarian cancer; however, little is known about prognostic patterns of CD8+ TILs by histotype and in relation to...
6.
Gayarre J, Kamieniak M, Cazorla-Jimenez A, Munoz-Repeto I, Borrego S, Garcia-Donas J, et al.
J Gynecol Oncol
. 2015 Oct;
27(1):e7.
PMID: 26463438
Objective: We aimed to evaluate the prognostic and predictive value of the nucleotide excision repair-related gene GTF2H5, which is localized at the 6q24.2-26 deletion previously reported by our group to...
7.
Kamieniak M, Rico D, Milne R, Munoz-Repeto I, Ibanez K, Grillo M, et al.
Mol Oncol
. 2014 Dec;
9(2):422-36.
PMID: 25454820
Standard treatments for advanced high-grade serous ovarian carcinomas (HGSOCs) show significant side-effects and provide only short-term survival benefits due to disease recurrence. Thus, identification of novel prognostic and predictive biomarkers...
8.
Lastra-Aras E, Robles-Diaz L, Guillen-Ponce C, Alba E, Cruz J
Clin Transl Oncol
. 2012 Aug;
15(1):20-5.
PMID: 22911548
Introduction: Approximately 5 % of all cancer cases are hereditary. Cancer genetic counseling assesses individual and family risks of cancer, conducts genetic studies, interprets results, and advises patients regarding strategies...
9.
Garcia M, Fernandez V, Osorio A, Barroso A, Llort G, Lazaro C, et al.
Breast Cancer Res Treat
. 2008 Feb;
113(3):545-51.
PMID: 18302019
Recent reports have shown that mutations in the FANCJ/BRIP1 and FANCN/PALB2 Fanconi Anemia (FA) genes confer a moderate breast cancer risk. Discussion has been raised on the phenotypic characteristics of...
10.
Robles-Diaz L, Goldfrank D, Kauff N, Robson M, Offit K
Fam Cancer
. 2004 Nov;
3(3-4):259-64.
PMID: 15516850
Ovarian cancer is the fourth leading cause of cancer deaths among American women. While women in both the Ashkenazi and non-Ashkenazi populations have an estimated 1.7% lifetime risk of acquiring...